Aclarion Reports $21.1K Q1 Revenue, Widens Net Loss to $2.85M
summarizeSummary
Aclarion, Inc. reported its first-quarter 2026 results from its 10-Q filing, revealing revenue of $21.1K and a net loss attributable to common stockholders of $(2.85M), or $(1.34) per diluted share. This filing provides the definitive financial performance for Q1, following an earlier news release on April 30th that qualitatively described Q1 2026 as "strong" based on scan volumes but did not include these specific financial figures. While diluted EPS significantly improved year-over-year from $(9.32) to $(1.34), the company's revenue remains extremely low, and its net loss widened from $(2.04M) to $(2.85M) year-over-year, driven by increased commercialization and operating costs for scaling its NOCISCAN® offering. For a micro-cap company, this widening net loss and minimal revenue are material concerns, despite operational growth in U.K. scan volumes and a strengthened cash position from recent equity financing. Investors will closely monitor the company's ability to translate operational expansion into substantial revenue growth and reduced net losses in future quarters.
At the time of this announcement, ACON was trading at $3.28 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.5M. The 52-week trading range was $2.34 to $12.03. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Wiseek News.